High and constant plasma levels of tissue plasminogen activator and PEG- hirudin can be achieved by subcutaneous delivery

Thrombosis Research

Volumn 87, Issue 1, 1997, Pages 123-129

  Humphries, Julia ^a   Lattimer, Christopher ^a   Smith, Alberto ^a   McGuinness, Catharine L ^a   Whitton, Colin ^b   Gaffney, Patrick J ^b   Burnand, Kevin G ^a  

^a ST THOMAS HOSPITAL   (United Kingdom)

^b NATIONAL INSTITUTE FOR BIOLOGICAL STANDARDS AND CONTROL   (United Kingdom)

Author keywords

Cholesterol fed; Polyethylene glycol recombinant hirudin; Rabbit; Recombinant tissue; Subcutaneous; Type plasminogen activator

Indexed keywords

ALTEPLASE; CHOLESTEROL; ECARIN; LEPIRUDIN; MACROGOL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; CORONARY ARTERY DILATATION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CONJUGATION; DRUG HALF LIFE; INTRAVENOUS DRUG ADMINISTRATION; NONHUMAN; PRIORITY JOURNAL; RABBIT; SUBCUTANEOUS DRUG ADMINISTRATION; THROMBOSIS;

ANIMALS; ANTITHROMBINS; DIET, ATHEROGENIC; HIRUDINS; INJECTIONS, SUBCUTANEOUS; PLASMINOGEN ACTIVATORS; RABBITS; THROMBOSIS; TISSUE PLASMINOGEN ACTIVATOR;

EID: 0030879056     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0049-3848(97)00111-4     Document Type: Article

References (14)

1. FANELLI, C. and AORONOF, F. Restenosis following coronary angioplasty. Am. Heart J. 119, 357-368, 1990.
2. FARB, A., VIRMANI, R., ATKINSON, J.B. and KOLODGIE F.D. Plaque morphology and pathological changes in arteries from patients dying after coronary balloon angioplasty. J. Am. Cardiol. 16, 1421-1429, 1990.
3. CASSCELLS, W. Smooth muscle growth factors. Prog. Growth Factor Res. 3, 177-206, 1991.
4. SAREMBOCK, I..J., GERTZ, D.S., GIMPLE, L.W., OWEN, R.M., POWERS, E.R. and ROBERTS, W.C. Effectiveness of recombinant desulphatohirudin in reducing restenosis after balloon angioplasty of atherosclerotic femoral arteries in rabbits. Circulation 84(1), 232-243, 1991.
5. COLLEN, D, LIJNEN, H.R., New approaches to thrombolytic therapy. Arteriosclerosis 4, 579-585, 1984.
6. GARCIA FRADE, L.J., POOLE, S., CREIGHTON L.J., CURTIS, A.D. and GAFFNEY, P.J. Unavailability in rats of human recombinant tissue plasminogen activator after subcutaneous and intramuscular injection. Thrombosis. & Haemostatasis 56, 299-301, 1986.
7. MARKWARDT, F. Pharmacology of hirudin : One hundred years after the first report of the anticoagulant agent in medicinal leeches. Biomed. Biochem. Acta. 44, 1007-13, 1985.
8. RÜBSAMEN, K., HORNBERGER, W., SCHWEDEN, J. and KURFÜST, M. Pharmacological characteristics of a long-acting polyethylene glycol coupled recombinant (LU 56471). Thrombosis. & Haemostasis 65(6), 1291, 1991.
9. MAHMOUD, M., GAFFNEY, P.J. Bioimmunoassay (BIA) of tissue plasminogen activator (t-PA) and its specific inhibitor (t-PA-INH). Thrombosis & Haemostasis 53(3), 356-359, 1985.
10. GAFFNEY, P.J. Tissue plasminogen activator for thrombolytic therapy. Expectation versus reality. J. Roy. Soc. Med. 85, 692-698, 1992.
11. SOBEL, B.E., FIELDS, L.E., ROBISON, A.K., FOX, K.A.A. and SARNOFF S.J. Coronary thrombolysis with facilitated adsorption of intramuscularly injected tissue type-plasminogen activator. Proc. Natl. Acad. Sci. USA 82., 4258-4262, 1985.
12. EßLINGER, H.U., GREGER, G., LAßMANN, A. and MAURER, R. General tolerability and effects on clotting parameters after single i.v. and s.c. bolus administration of recombinant hirudin (LU52369) in man. Thrombosis & Haemostasis 65(6), 129, 1991.
13. FAREED, J., WALENGA, J..M., HOPPENSTADT, D., IQBAL, O. and. RÜBSAMEN, K. Comparative pharmacodynamics /pharmacokinetics of recombinant hirudin and its PEG-coupled derivatives in primates. Thrombosis.& Haemostasis. 65 (6), 1286, 1991.
14. HORNBERGER, W., RÜBSAMEN, K. and SCHWEDEN, J. Prolonged use of a new polyethyleneglycol-coupled hirudin (LU57291) in two rat thrombosis models. Ann. Haematol Suppl. 1:A20, 1993.